Search

Displaying results 5531 - 5540 of 9322 in total
  1. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  2. Drug

    Tepoxalin

    go.drugbank.com/drugs/DB11466
    ExperimentalVet approved

    Tepoxalin is a nonsteroidal anti-inflammatory drug approved for veterinary use in the United States and many other countries. … It is primarily used to reduce inflammation and relief of pain caused by musculoskeletal disorders such as hip dysplasia and arthritis.

  3. Drug

    SIG-007

    go.drugbank.com/drugs/DB17710
    Experimental

    Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.

  4. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    for the treatment of advanced non-small cell lung cancer (NSCLC). … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated

  5. Drug

    Escin

    go.drugbank.com/drugs/DB15907
    Investigational

    Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and

  6. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)

  7. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  8. Drug

    5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08722
    Experimental

    This compound belongs to the phenol ethers. … These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole targets the protein genome polyprotein

  9. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  10. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.